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Summary: A new mouse model for systemic infection 
with Escherichia coli is presented. Whereas in other 
models 107_108 bacteria have to be injected into an ani-
mal to induce toxic effects resulting in death within 24 
hours, now, only 103_104 bacteria of an appropriate 
strain are required to produce a genuine infection 
characterized by an increase in the bacterial load over 
several days. The quantitative determination of bacte-
rial counts per liver allows a more sensitive measure-
ment than recording death rates. Furthermore, few 
animals are required for a definite result in contrast to 
the LDso determination of other models. The salient 
point regarding this new model is that conditioning of 
animals has to be achieved by incorporating the inocu-
lum into agar which is injected subcutaneously. The re-
sulting infection is completely dependent on the E. coli 
Zusammenfassung: Vergleichende therapeutische Akti-
vitiiten von Ciprof/oxacin, Amoxicillin, Ceftriaxon und 
Co-trimoxazol in einem neuen Versuchsmodell fur die 
experimentelle Infektion mit Escherichia coli. Ein neu-
es Mausmodell fur eine systemische Infektion mit 
Escherichia coli wird vorgestellt. In anderen Infek-
tionsmodellen mussen 107_108 E. coli pro Maus inji-
ziert werden, was zu einer Intoxikation fUhrt, so daB 
die Tiere innerhalb von 24 Stunden sterben. In diesem 
neuen Modell wird eine echte Infektion mit nur 
103-104 Bakterien gesetzt, und es folgt dann uber meh-
rere Tage hinweg eine deutliche Vermehrung der Er-
reger. Diese kann exakt quantitativ durch die Bestim-
mung der Keimzahlen in der Leber kontrolliert wer-
den, was eine viel empfindlichere Methode darstellt als 
die Feststellung von Mortalitatsraten. Weiterhin wer-
den dabei weitaus weniger Mause benotigt, urn eine 
stichhaltige Aussage zu machen, als fUr eine Bestim-
mung der LDso erforderlich sind. Der entscheidende 
Punkt dieses neuen Modells ist, daB die Infektion mit 
den niedrigen Keimzahlen gebahnt werden muB. Dies 
Introduction 
It is hard to define the therapeutic potential of a chemo-
therapeutic agent only by determining its in vitro activity, 
since many pharmacological and infectiological aspects 
cannot be simulated under these relatively simple condi-
strain used. Whereas a hemolytic, uropathogenic 
strain is so virulent that an overwhelming infection de-
velops within 48 hours after the injection of 103 bacte-
rial cells, a non-hemolytic variant of this strain is com-
pletely avirulent, being unable to multiply in spite of 
the potentiating agar. The hemolytic E. coli strain 
ATCC 25922 is intermediate in virulence. The bacte-
rial counts per liver increase steadily until death occurs 
five to seven days after the injection of 104 bacteria. 
This bacterial infection can be therapeutically influenc-
ed by daily treatment with various drugs. Ciprofloxa-
cin, ceftriaxone and co-trimoxazole are able to cure 
the infection, whereas amoxicillin given orally is only 
moderately active against this ATCC strain, which is 
relatively resistant to amoxicillin. 
geschieht dadurch, daB das Inokulum in verflussigtem 
Agar suspendiert wird, bevor es subkutan injiziert 
wird. Der Infektionsverlauf ist wesentlich abhiingig 
von der Natur des verwendeten E. coli-Stammes. 
Wahrend z. B. ein hamolytischer, uropathogener 
Stamm so virulent ist, daB die Tiere einer fulminanten 
Infektion nach Injektion von nur 103 Keimen erliegen, 
ist eine nicht-hamolytische Mutante dieses Stammes 
vollig avirulent und kann sich selbst trotz der Beigabe 
von Agar nicht vermehren. Der hamolytische Stamm 
E. coli A TCC 25922 ist bezuglich seiner Virulenz inter-
mediar, d. h. nach Injektion von 104 Bakterien nimmt 
die Keimzahl pro Leber standig zu und die Tiere ster-
ben nach funf bis sieben Tagen an dieser Infektion. 
Gerade dieser Infektionsverlauf kann durch tagliche 
Verabreichung von Chemotherapeutika beeinfluBt 
weT-den. Ciprofloxacin, Ceftriaxon und Co-trimoxazol 
sind in der Lage, eine Ausheilung zu erzielen. Amoxi-
cillin hat nach oraler Gabe nur eine maBige Wirkung 
aut die Infektion mit diesem ATCC-Stamm, der auch 
gegen Amoxicillin relativ resistent ist. 
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tions. Thus, it is of special interest to test the efficacy of 
an antimicrobial substance in an in vivo model. 
In this paper a new model of systemic infection in mice 
with Escherichia coli is described which seems to be suit-
able for therapeutic studies. 
This new model is derived from the experimental design 
of Joiner et al. (1) and Reznikov, Hackendorf and Mat-
thews (2). They infected animals subcutaneously with a 
combination of E. coli and Bacteroides fragilis suspended 
in a potentiating material. Whereas E. coli produces a 
systemic infection, B. fragilis is only found in a local ab-
scess at the site of injection. We have found that a syner-
gistic action of B. fragilis is obviously not necessary. Cer-
tain strains of E. coli alone, suspended in semi-solid agar 
as the potentiating material (3), are also able to produce a 
systemic infection which can be monitored quantitatively 
for several days by determining bacterial counts in the 
liver. 
Using this new model, the therapeutic activity of cipro-
floxacin, a new quinolone with high antibacterial (4) and 
therapeutic (5) activity, was examined and compared with 
that of well known antibacterial agents, such as amoxicil-
lin, co-trimoxazole and ceftriaxone. 
Materials and Methods 
Bacteria: Bacteria were grown in tryptose phosphate broth (Dif-
co, Detroit, U.S.A.) for 18 h at 37°C. Appropriate dilutions 
were prepared in phosphate-buffered saline (PBS), pH 7.2. The 
E. coli strains used were strain 536 (06:KI5:H31), its non-he-
molytic mutant 536/21 (5) and strain ATCC 25922. The nalidixic 
acid-resistant mutants II, III and IV of E. coli ATCC 25922 
were obtained by MNNG mutagenesis (6). 
Antibacterial agents: Quinolones: nalidixic acid was bought from 
Sigma (Munich, F.R.G.). Ciprofioxacin (Pt.No. 958508; 84.8% 
activity) was a gift from Bayer AG (Leverkusen, F.R.G.). 
Trimethoprim and sulfamethoxazole were obtained from Hoff-
mann-La Roche (Grenzach, F.R.G.) and were used in a ratio of 
1:20 for in vitro tests. For the treatment of animals, the combi-
nation co-trimoxazole (Bactrim®) was used containing both sub-
stances in a ratio of 1:5. Ceftriaxone (Op. No. PT 3455; 81. 5% 
activity) was a gift of Hoffmann-La Roche, Basel, Switzerland. 
Amoxicillin (amoxicillin trihydrate BRL 2333; 86% activity) 
was kindly supplied by Beecham, Neuss, F.R.G. 
Determination of minimum inhibitory concentration (MIC): An 
agar dilution method was employed using Mueller-Hinton agar 
as nutrient. 0.6 J-tl of a bacterial suspension adjusted to one half 
of a McFarland's No. 1 standard was transferred by means of a 
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multipoint inoculator (Greiner, Niirtingen, F.R.G.) to the agar 
plates containing the different concentrations of the antimicro-
bial agents. The inoculated plates were incubated for 24 h at 
37°C. The MIC was taken as the lowest concentration of the an-
tibacterial agents which did not allow visible growth. 
Determination of in vivo activities: Female NMRI mice weighing 
about 25 g were obtained in SPF-state from the Central Institute 
for Laboratory Animals (Hannover, F.R.G.). They were held 
under conventional conditions and fed water and pellets ad libi-
dum. 0.3 ml of a bacterial suspension was mixed in the syringe 
with 0.5 ml of 1.5% liquified tryptose phosphate agar (48°C) and 
immediately injected subcutaneously into the back of a mouse. 
the bacterial counts in the suspension were determined by plat-
ing. Their numbers ranged from 103 to 106 in the various experi-
ments. 
Treatment with ciprofioxacin was initiated 6h after infection. 
2 mg, i.e. 80 mg/kg, of this drug dissolved in 0.5 ml water were 
given orally by means of a stomach tube twice a day. Similar 
doses of amoxicillin were also given orally, whereas co-trimoxa-
zole as well as ceftriaxone were injected subcutaneously. 0.2 ml 
of a preparation were injected at alternate sites into the back of 
an animal. 
At different intervals after infection, five mice from each group 
were killed and the liver, as well as the spleen and kidneys, in 
some experiments were removed aseptically. The organs were 
homogenized in a Tenbroek tissue grinder (Bellco, Vineland, 
N.l., U.S.A.). Serial dilutions in PBS were transferred into Pe-
tri dishes and mixed with 20 ml of liquified tryptose phosphate 
agar. After incubation at 37°C for 24 h the bacterial colonies 
were counted and the bacterial counts per organ were calcu-
lated. 
Results 
Determination of the Minimum Inhibitory Concentration 
The parent strain ATCC 25922 was susceptible to amoxi-
cillin, ceftriaxone, co-trimoxazole, nalidixic acid and cip-
rofloxacin, the latter substance being the most active 
compound. The three nalidixic acid-resistant mutants 
were also relatively resistant to ciprofloxacin (Table 1). 
Conditioning of Escherichia coli Infection in Mice 
The subcutaneous injection of 108 cells of E. coli was le-
thal for mice, whereas 106 cells were well tolerated (Table 
2). One day after infection, virtually no bacteria could be 
isolated from the spleen or liver (data not shown). How-
ever, when 106 cells mixed with agar were injected, the 
animals appeared ill and died within a few days (Table 2). 
Table 1: In vitro susceptibilities of Escherichia coli to different antibiotics. 
Escherichia coli 
ATCC 25922 
Mutant II 
Mutant III 
Mutant IV 
, , 
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Table 2: Conditioning of infections of NMRI mice by mixing 
the bacterial suspension with agar. 
.. AJililbal,St<lup Survival rate 
Subcutaneous injection of 0/10' 
lOB Escherichia coli ATCC 25922 
Subcutaneous injection of 10/10 
106 Escherichia coli A TCC 25922 
Subcutaneous injection of 0/10"" 
106 Escherichia coli A TCC 25922 
suspended in agar 
• Mice died within 24 h; 
" Mice died within 3-5 days. 
A multiplication of bacteria apparently took place under 
these conditions, since the bacterial numbers in the liver 
determined on the days following infection definitely ex-
ceeded the inoculum dose. Different strains of E. coli var-
ied in their ability to multiply within the host (Figure 1). 
Therapeutic Studies 
In untreated control mice infected with E. coli A TCC 
25922, high bacterial counts were found in the liver and 
the animals died five days after infection. Oral treatment 
with 2x2 mg ciprofloxacin prevented death and resulted 
in a marked reduction of the bacterial counts. Even the 
moderately resistant mutant strain was eliminated, 
though somewhat less rapidly (Figure 2). 
Treatment with 2x2 mg co-trimoxazole or with 2x2 mg 
ceftriaxone/day was also very efficient (Figure 3), where-
as oral treatment with 2x2 mg amoxicillin/day was rather 
ineffective (Figure 3). 
Discussion 
The addition of a potentiating agent, for example agar, to 
the inoculum is a prerequisite for the establishment of 
true infection of mice with E. coli (Table 2). It is possible 
that the subcutaneous agar depot inaccessible to the de-
fense mechanisms of the host inhibits rapid clearing of the 
infection. Local multiplication of bacteria may provide a 
focus from which spreading to distant organs may occur. 
On the other hand, invasion of the internal organs may be 
promoted by agar, which damages certain systemic de-
fense systems (7). 
Not every strain of E. coli, however, is able to multiply 
under such conditions (8). Injection of virulent strains re-
sults in the death of the animals within one or two days, 
whereas subcutaneous injection of avirulent strains has no 
effect in this model. The strain E. coli A TCC 25922 is of 
intermediate virulence, meaning that the development of 
a persistent infection is dependent on the infective dose 
(Figure 1). Various virulence factors, including hemolysin 
and fimbriae, contribute to the pathogenic potential of a 
strain (9). 
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Figure 1: NMRI mice were infected subcutaneously with 
5x103 cells of Escherichia coli 536 (0), ATCC 25922 (0) or 
536/21 (L,) incorporated in agar. The mean ± SE of bacte-
rial counts per liver of five animals per group and day was 
determined. 
The advantage of the experimental model of systemic in-
fection of mice with E. coli A TCC 25922 that is presented 
here is that low infective doses (about 103 bacteria) can be 
used for infection. Rapid multiplication clearly takes 
place in the animal, since 24 hours after subcutaneous in-
jection, many more bacteria can already be isolated from 
the spleen, and especially from the liver, than were pres-
ent in the inoculum. This infectious process continues for 
several days, depending on the infective dose. Conse-
quently, the therapeutic efficacy of a drug can be mon-
itored continuously. This model therefore differs funda-
mentally from other animal models where high, i.e. lethal 
doses of E. coli have to be injected (9). The premature 
death of animals injected with 107 bacteria or more is due 
to toxic effects rather than to infection (Table 2). Further-
more, only small numbers of animals are required in this 
new model to achieve a definitive characterization of the 
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Figure 2: NMRI mice were infected subcutaneously with 
104 cells of Escherichia coli ATCC 25922 (0) or its nali-
dixic acid-resistant mutant IV (e) incorporated in agar. 
Mice from both groups were treated orally with 2x2 mg 
ciprofloxacin/day beginning 6 h after infection 
(---o--/--e--). The mean ± SE of bacterial counts 
per liver of five animals per group and day were determin-
ed. 
therapeutic activity of a certain drug, whereas large 
numbers of mice are required for the determination of an 
EDso, which is a rather insensitive parameter. 
Ciprofloxacin, an inhibitor of the subunit A of bacterial 
gyrase (10), proved to be a very potent drug in this model 
since susceptible bacteria (Table 1) were eliminated very 
rapidly by oral treatment with 80 mg/kg twice daily. Even 
infection with the relatively resistant strain (Table 1) ob-
tained by mutagenesis can be cured, although these bacte-
ria disappear less rapidly (Figure 2). As reported by Smith 
(11), a high degree of resistance to ciprofloxacin could not 
be achieved by mutagenesis with MMNG, although these 
mutants were completely resistant to nalidixic acid (Table 
1). 
The therapeutic efficacy of 2x80 mg/kg/day of amoxicil-
lin given orally was rather low (Figure 3). This could be 
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due either to a partial absorption of the drug or to the rel-
atively low in vitro susceptibility of the E. coli A TCC 
25922 strain, showing an MIC of 4 mg/l (Table 1). In con-
trast, a similar dose of ceftriaxone, given parenterally, 
was curative. Co-trimoxazole was also able to eliminate 
the bacteria. 
In conclusion, it appears that this model of systemic infec-
tion with E. coli following local injection of low doses is 
suitable for the therapeutic evaluation of antibacterial 
agents . 
6 
5 .-.-.~.-.-.-. -'2·-' 
.... 
Q) 4 
.~ 
.... 
Q) 
a. 
.-
"0 (,) 
.~ 3 
..c:: (,) 
.;:: 
CIl 
..c:: (,) 
l[j 
~ 2 Cl 
0 
.....J 
~ 
'\ 
" 
t·· . "~" " • '\ 
• 
• '\ 
• '\ 
• 
• '\ 
• 
3 6 
days after infection 
Figure 3: NMRI mice were infected sUbcutaneously with 104 
cells of Escherichia coli ATCC 25922 (-0-) incorporated 
in agar. Some mice were treated orally with 2x2 mg amoxi-
cillin (-.-.-0-.-.-) or subcutaneously with 2x2 mg co-
trimoxazole (- - -0- - -) or ceftriaxone ( .... 0 .... ). The mean 
± SE of bacterial counts per liver of five animals per group 
and day was determined. 
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